• BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products
• The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical studies
• So far, the preclinical studies have shown that the NanoAb results in significantly milder illness and faster recovery, eliminates the SARS-CoV-2 virus from the lungs, and prevents illness when administered prophylactically
• The FDA has revoked the authorization of multiple mAb treatments and one mAb prophylactic drug, creating a significant gap in a market that has shown strong demand for COVID-19 treatments
• BiondVax is uniquely positioned to meet this demand, backed by an extensive library of NanoAbs that allows it to rapidly develop neutralizing treatment as soon as a new variant emerges

The Food and Drug Administration (“FDA”) has, over the last two years, authorized several drugs as treatments for mild-to-moderate COVID-19 or as pre-exposure prophylaxis (“PrEP”) for the prevention of the disease. Most of these drugs were based on human monoclonal antibody (“mAb”) technology and were designed to boost the immune system by mimicking natural neutralizing antibodies. The mAbs would bind with the SARS-CoV-2 virus’ receptor binding domain, a section of the viral spike protein, preventing it from entering the patient’s cells and exacerbating the infection.

However, the virus has continually mutated as it works to correct ‘flaws’ that make it vulnerable to treatment. This has rendered previously authorized mAb treatments ineffective, with the FDA progressively revoking authorizations for these therapies as a result. For example, in November last year, the agency deauthorized bebtelovimab, the last of the COVID-19 treatment antibodies. And in January, a similar fate befell AstraZeneca PLC (NASDAQ: AZN)’s Evusheld, which was designed as a PrEP treatment (https://ibn.fm/OBKpX), and in the first nine months of 2022 generated $1.5 billion in sales, a testament to the huge demand for proactive COVID protection.

Although other non-monoclonal-antibody therapies remain authorized, none can be administered as PrEP for the prevention the COVID-19 disease, according to the FDA’s Emergency Use Authorization webpage (https://ibn.fm/41gyW). Furthermore, Pfizer Inc. (NYSE: PFE)’s Paxlovid, which is still effective against the new subvariants of the Omicron variant, has multiple contraindications for common drugs including blood thinners, heart medications, and prescribed statins. Those patients who were ineligible to receive Paxlovid would have previously received mAb-based drugs. But this is no longer the case.

“Encouragingly,” Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV), wrote in his letter to shareholders published December 30, 2022 (https://ibn.fm/b62Lh), “our lead NanoAb candidate, currently being prepared for clinical trials, has demonstrated neutralization of all relevant Omicron subvariants.”

Reichman was highlighting one of the outstanding benefits of the company’s alpaca-derived nanosized antibodies (“NanoAbs”), which exhibit potential superior therapeutic capabilities for a wide range of diseases, including COVID-19. BiondVax, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has so far shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits significant competitive advantages over existing mAbs and oral therapies.

According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically. The first set of results, announced January 6, showed that a group of COVID-19-infected hamsters that were treated with the company’s inhaled anti-COVID-19 therapy had over 30x lower lung viral titer on average than the placebo group. These results built on previously announced data, which indicated that the NanoAb treatment led to significantly milder illness and faster recovery compared to the placebo group (https://ibn.fm/MGKRe).

The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection, it virtually prevented the hamsters from contracting the illness. In particular, the hamsters that received the inhaled NanoAb experienced no significant weight loss over the six-day trial, while the untreated control groups’ weight reduced by 12% on average (https://ibn.fm/WQZSQ). This data shows the prophylactic capabilities of the NanoAb, positioning the company to fill the huge void left by the withdrawal of Evusheld’s authorization.

BiondVax, which aims to replicate in human trials the efficacy demonstrated so far in its animal studies, believes there will continue to be a strong market demand for COVID prophylactics and treatments. This belief is supported by Pfizer’s recent report (https://ibn.fm/ffSCz), suggesting that revenues from COVID products is expected to grow in 2024. Backed by libraries with millions of COVID-19 NanoAb candidates developed by its collaborators at the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), BiondVax is well positioned to meet the demand.

“Indeed, the emergence of new variants remains a concern, and NanoAb therapeutics have the potential to quickly and effectively address new variants,” Reichman’s letter continues. “Our collaborators at MPI and UMG have generated libraries, each with ~300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb”.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• D-Wave’s Qubits annual user conference, currently in its seventh year, is one of the industry’s premier quantum computing events differentiated by its focus on real-world applications of quantum technology
• The company displayed its continued commercial customer momentum and real-time product innovation, reflecting the increasing enterprise adoption of quantum computing solutions
• The conference demonstrated how D-Wave’s proprietary technology helps organizations solve highly complex business problems today

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, announced new and renewed commercial customer engagements and product updates for its annealing and gate-model quantum computing solutions during the company’s annual Qubits 2023 user conference. The company’s continued commercial customer momentum and product innovation reflect the increased adoption of quantum computing solutions and showcase the technology’s ability to solve businesses’ most challenging computational problems today (https://ibn.fm/dRRdr).

The Qubits event, now in its seventh year, is one of the industry’s premier quantum computing events and is differentiated by its focus on the real-world application of quantum technology to today’s business problems. Quantum-hybrid applications on display at Qubits included solutions from: Mastercard (customer loyalty and rewards allocation), Davidson Technologies (missile defense optimization), Recruit Group (TV commercial allocation), Pattison Food Group (grocery operations optimization), SavantX (port operations optimization), and many more. In addition to showcasing commercial quantum applications during the conference, D-Wave announced that it had added several new high profile customers to its portfolio, working on a diverse set of potential use cases. New and renewing commercial customers working with D-Wave on quantum-hybrid use cases include Siemens Healthineers, Unisys, and Davidson Technologies. These companies are exploring various applications that span medical imaging, military defense optimization, and vehicle routing.

In the event keynote, Dr. Alan Baratz, CEO of D-Wave, outlined that practical quantum computing solutions are becoming essential to helping businesses compete, innovate, and grow. “As we gather at our annual Qubits user conference in Miami this week, the commercialization of quantum is on full display. Currently, more than 60 companies are working with us on real-world quantum-hybrid applications that are unlocking business value today,” Dr. Baratz underlined. “Unlike other modalities, annealing quantum computing is commercial-grade and enterprise-ready, and customers are realizing the benefits of this powerful technology now.”

During the conference, D-Wave shared the progress made toward its next-generation Advantage2^TM annealing quantum computing system, expected to feature 7000+ qubits and 20-way connectivity, which will be implemented in a new lower-noise fabrication stack to enable customers to solve incrementally more complex problems with greater precision.

D-Wave also showcased several recent enhancements to its constrained quadratic model (“CQM”) hybrid solver in its Leap cloud service. These include continuous variables that enable better representation of constrained problems, the handling of weighted restraints that allow quantum developers to more easily and accurately model problems, and pre-solve techniques that reduce the size of problems and allow for larger models to be submitted to the hybrid solver.

Other milestones shared by D-Wave during the event covered the scalable qubit design and readout method validation and the company’s gate-model simulator launched in the Ocean suite of open-source tools. “Our relentless and on-time product delivery reflects a deep commitment to ongoing innovation that accelerates quantum computing adoption, usage and customer value,” Dr. Baratz added. “Through the continued development of our quantum annealing and gate model quantum solutions, we’re focused on building and delivering the full breadth of quantum solutions to our customers, both today and into the future, bringing our unique cross-platform vision to life.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

DX3 is a leading event management enterprise, organizing summits and trade shows that unite retail, marketing, and technology professionals, leaders, and businesses, on a single floor. They strive to bring meaningful and informative content under one roof, offering a learning and networking opportunity to these industries for better expansion and growth.

The experts offer industry insights and gather innovation solutions from international speakers as they conduct discussions, workshops, and meetings at the DX3 Canada 2023 Summit. Be a part of the panel discussions, witness tech demonstrations, and participate virtually in hybrid exhibitions to learn the most advanced and sophisticated skills from industry specialists. It is a great learning and marketing platform for newbies and reputed business firms alike where 2000 attendees, 150+ leading speakers, and 15+ exhibitors network, interact and discover new business avenues.

Some important topics include:

• Expert insights on achieving brand authenticity and transparency
• Tech keynotes
• Discussion of future retail trends and technologies over the next decade
• Retail online marketing transformation
• Changes in consumer behavior and preferences post-pandemic
• Marketing in the 2020 decade
• Traditional vs modern retail marketing
• Augmented reality for better shopping experiences
• Panel discussions on the emergence of private brands
• Immersive marketing strategies: case studies and discussions
• Leveraging the eCommerce boom
• Data management while ensuring consumer trust
• Inclusivity in workplace
• Decoding social, political, and economic consumer segmentation
• Scaling influencer marketing
• Decoding product discovery and consumer preferences
• Improving consumer experiences

At the DX3 Canada summit, keynote speakers will discuss relevant topics in digital marketing, retail, and new technological advances. In today’s world, as retail and technology go hand-in-hand, it’s critical that attendees learn the strategies and intricacies of eCommerce, digital marketing, and other tech-driven tools for their businesses, face-to-face from the experts.

The president and CEO, Hifazat ‘Faz’ Ahmad, has been focusing on expanding and growing business conference organizations across several continents. Connect and interact with industry leaders as they reveal their success stories on growth, advancement, and efficiency.

To learn more, please visit https://ibn.fm/m1loW.

• SideChannel recently released its financial results for Q1 2023, recognizing $1,546,000 in revenue, a 48% year-over-year increase
• The company also ended the fiscal quarter with $2,553,000 in cash, having spent about $480,000 to offset R&D and marketing expenses
• SideChannel is in the business of providing cybersecurity leadership and program development through its team of virtual Chief Information Security Officers (“vCISOs”)
• The company has also developed Enclave, a micro-segmentation software that recently received FIPS 140 certification, opening the door for SideChannel to pursue federal and state contracts and further increase cybersecurity revenue

SideChannel (OTCQB: SDCH), a company focused on delivering cybersecurity programs as a service and complimentary solutions to small and middle-market companies that have long been priced out of cybersecurity solutions, recently announced its financial results for the quarter ended December 31, 2022 (“Q1 2023”). The company recognized a 48% year-over-year revenue growth from $1,048,000 in Q1 2022 to $1,546,000 in the just-ended quarter (https://ibn.fm/ZQIlD). Furthermore, the Q1 2023 revenue represented a 26% quarter-over-quarter growth from Q4 2022 figures.

In addition, the company closed off the year with $2,553,000 in cash, having used about $480,000 in the just-ended quarter to offset operational expenses. More specifically, these expenses included investments in a few growth initiatives, including research and development (“R&D”) expenditure to advance its micro-segmentation software Enclave as well as sales and marketing to acquire new clients, according to SideChannel CFO Ryan Polk. Ryan was speaking in the company’s financial-results conference call hosted February 13. A recording of the call is available on the company’s website at https://ibn.fm/YxdC4 (registration required).

“An increasing number of emerging and mid-market companies are recognizing the need for more robust cybersecurity programs to reduce the risks impacting their business, whether it is from increased regulation, customer demands, or Board-level oversight,” CEO Brian Haugli conveyed in a news release announcing the financial results. “These companies turn to SideChannel to provide cybersecurity leadership and program development through our team of virtual Chief Information Security Officers (‘vCISOs’). In the last twelve months, revenue from our vCISO practice has increased 66%.”

The company intends to continue delivering on its strategy, which emphasizes growing vCISO relationships while adding complimentary products, cybersecurity services, and privacy services to help its clients cost-effectively reduce risk. SideChannel recognizes that small and middle-market companies face growing needs for cybersecurity through software and services. However, the rising costs and rapid turnover of Chief Information Security Officers (“CISOs”) leave them priced out of the market for the talent they truly need. In addition, CISOs are burning out and are looking for a better way to practice the profession they love and bring real value to companies in need of their services.

“We, as SideChannel, marry these two,” said Haugli in the conference call. “We offer cybersecurity programs as a service via senior experienced CISOs to those mid-market companies and emerging tech and startups on a fractional, cost-effective basis. This offers SideChannel’s customers unparalleled expertise and support, but at a price that is appropriate to their budgets. Moreover, they can also benefit from our expansive team, deep vertical expertise, and the opportunity to source from a wide array of software and other tools from across the industry.”

One software SideChannel’s clients can benefit from is Enclave. According to Haugli, this micro-segmentation application reduces risk, enhances productivity, and makes zero-trust a reality. “We can deploy Enclave in a variety of ways, either through direct license sales or via a managed service. And the focus shift on Enclave is not just to deliver encryption, but also deliver through micro-segmentation more than just encryption itself,” Haugli explained.

Enclave, Haugli intimated, is now a FIPS 140-certified product. (Federal Information Processing Standards or FIPS define the data security and computer system standards that an organization must heed. One of these standards, the FIPS 140, requires the system to have at least one working encryption algorithm https://ibn.fm/dg3tX. The certification clears SideChannel to pursue federal and state contracts, which require FIPS 140 compliance, and be able to sell Enclave to government entities. Thus, looking ahead, SideChannel is well positioned to grow revenue from cybersecurity software even further, considering that Q1 2023 revenue from this stream witnessed a 28% year-over-year growth, according to Ryan.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• EverGen Infrastructure CEO, Chase Edgelow recently joined a webinar hosted by Adelaide Capital to provide investors and stakeholders with an update on the company’s operations
• Edgelow elaborated on the company’s portfolio, including its 4 existing revenue generating assets, 2 projects currently under construction as well as its Ontario-based Greenfield project, Project Radius
• By 2Q 2023, EverGen anticipated that the completion of its RNG projects would drive gross generating capacity to 240,000 GJ/annum, whilst growing EBITDA by $5-7m per year
• In the longer term, successful execution on EverGen’s Ontario-based Greenfield project could see the company expand its RNG production by as much as 1.7 million GJ/year

British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long held aspirations of transforming into Canada’s leading RNG infrastructure platform, in the process securing strong long-term contracted cash flows. The company today operates 4 revenue generating assets across 3 key regions in Canada, alongside 2 RNG projects currently under construction as well as one Ontario-based project in development. EverGen Infrastructure Corp CEO, Chase Edgelow recently participated in a webinar hosted by Adelaide Capital to provide investors with an update on the company’s ongoing operations as well as their prospects going forward (https://ibn.fm/XPI4q).

Edgelow revealed that following the completion of its two RNG projects currently under construction, namely Fraser Valley Biogas and GrowTEC, both of which are anticipated to be ready as of the end of Q1 2023–EverGen Infrastructure will see its built-up capacity expanded to 240,000 gigajoules of RNG per annum, a growth which could drive an additional $5-7 million dollars worth of EBITDA per year for the company. Meanwhile and on a longer-term basis, EverGen is simultaneously pursuing the expansion of all its ongoing projects through a broad-based $45m pre-funded capital expenditure plan; successful completion of all its initiatives will see the company grow its cumulative gross generating capacity to 480,000 gigajoules of renewable natural gas on an annual basis, whilst simultaneously tripling EverGen’s current run-rate EBITDA.

Over 37 billion tons of carbon emissions are released into the world’s atmosphere on a yearly basis (https://ibn.fm/uMUVl); in one recent study, BNY Mellon estimated that over $100 trillion in investments was necessary to tackle emissions if the world was to successfully achieve its stated Net Zero ambitions by 2050 (https://ibn.fm/XMRTj). Today and with over $1 trillion being invested annually into building out clean energy capacity (https://ibn.fm/0MS7Z), EverGen Infrastructure Corp finds itself operating at the center of what former Bank of England Governor, Mark Carney, referred to as the “greatest commercial opportunity of our age.”

EverGen Infrastructure’s path to becoming one of Canada’s largest RNG platforms owes its origins to the province of British Columbia’s decision in March 2017 to amend the Greenhouse Gas Reduction Regulation. The amendment, which sought to increase the production and use of renewable gas as well as green and waste hydrogen in British Columbia to simultaneously generate jobs and economic opportunities while reducing GHG emissions, has played a significant role in driving the sector’s growth prospects in recent years.

Since starting its operations and expanding its presence in British Columbia to three operating assets, EverGen Infrastructure made a bold decision to expand its presence nationwide over the past year. In 2022, the company broadened its Canadian footprint by acquiring a 67% stake in GrowTEC, an Alberta-based biogas project. EverGen would subsequently go on to purchase a 50% ownership in a large joint venture consisting of three high-quality, on-farm RNG projects in Ontario dubbed Project Radius.

It is within the latter Greenfield project that EverGen Infrastructure could stand to make its fortunes. Project Radius, located in southern Ontario, is a late-development-stage portfolio of three high-quality, on-farm RNG projects, collectively capable of producing ~1.7 million GJ/year of RNG that will contribute to the reduction of emissions from agricultural operations in southern Ontario. Each of the three projects is expected to produce ~550,000 GJ/year and will be constructed throughout 2023 and 2024.

“The acquisition of Project Radius provides a foothold in Ontario – a new and strategic jurisdiction in which EverGen can continue to participate in the consolidation and growth of the RNG industry in the near-term, as well as benefit from project economics in line with or exceeding those we have seen with our initial projects,” said Chase Edgelow, CEO of EverGen (https://ibn.fm/VBO5H). “Working alongside Northeast to advance the projects, EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually.”

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world’s leading anti-seizure medications
• During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals
• Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. In a letter to shareholders last month, Lexaria CEO Chris Bunka provided a thorough strategic update and insight into the company’s plan moving forward.

Mr. Bunka expressed how the current state of the economy has presented challenges to companies, especially during 2022. Still, Lexaria has navigated these challenges well by focusing on the things it can control, such as applied R&D designed to entice others to work with the company commercially. Despite inflation running at a 40-year high and 2022 stock markets experiencing the longest protracted decline since 2008, Lexaria is forging ahead – increasing staff and successfully handling an unprecedented volume of work (https://ibn.fm/K4s9R).

During 2022, Lexaria’s R&D pursuits were a success, firmly establishing the company as one of the world’s leaders in the investigation of cannabidiol (“CBD”) for controlling human blood pressure and demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications. Lexaria expects that 2023 will be full of additional R&D developments.

Lexaria’s expectations for Q1 2023 include the following:

• Additional results from hypertension study HYPER-H21-4
• Dosing completion in the company’s animal dementia study
• Dosing completion in the company’s animal diabetes study
• Dosing completion in human nicotine study NIC-H21-1
• Submissions and publishing of additional results in research journals

Also in 2023, Lexaria expects to file its Investigational New Drug (“IND”) application and receive approval from the US Food and Drug Administration (“FDA”) to commence the IND clinical study. The study will be a major step in the company’s maturation as a pharmaceutical company and will be its primary research focus once it commences.

Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide. The technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine, and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. It is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, oral suspensions and more.

DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients – increasing effectiveness and improving the way APIs enter the bloodstream. The benefits of DehydraTECH include faster delivery of the drug, increased bioavailability, increased brain absorption, improved drug potency, reduced drug administration costs, and masks unwanted taste, removing the need for additional sweetening ingredients.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and, reduce the time of onset from one to two hours to just minutes.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Export services under NAFTA, mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021
• With the transition from NAFTA to USMCA, trade in goods and services is set to see a spike from 2022 going forward, and Fr8Tech expects to capitalize on this
• Freight Technologies Inc., with its superior freight platform for North American cross-border shipping, yielded a 45% YOY revenue growth for Q2 2022, which it looks to surpass in the subsequent quarters of the current financial year
• With trucks moving about 70% of North American surface trade by value, trucking companies, Fr8Tech included, are set to be the biggest beneficiaries with the USMCA, enjoying benefits such as reduced administrative burdens and faster shipping times
• The USMCA’s objective is to support a mutually beneficial trade that seeks to achieve more accessible markets, fairer trade, and economic growth in North America. Fr8Tech looks to capitalize on opportunities that present themselves to not only create shareholder value but also grow its brand equity and realize its short-term and long-term objectives

According to the United States Census Bureau, the export of services under the North American Free Trade Agreement (“NAFTA”), mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021. The same applies to the trade of services between the U.S. and Canada. With the transition from NAFTA to the United States-Mexico-Canada Agreement (“USMCA”), it is projected that trade in goods and services in the region will not be altered. The study projects that operations in this sector will soar as trade among the three countries grows (https://ibn.fm/2BEFI).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an enterprise developing solutions to optimize and automate the supply chain process and offering a platform for B2B cross-border shipping in the NAFTA (now USCMA) region looks to capitalize not just on the smooth transition, but also the relatively unaltered trade in goods and services to grow its market share and achieve its revenue objectives. This level of focus has allowed the company to achieve a 45% year-over-year (“YOY”) revenue growth for the second quarter of the 2022 financial year, which It looks to surpass in the subsequent quarters of the current financial year (https://ibn.fm/IDih3).

The shift from NAFTA to USMCA came in the wake of proposed amendments to the initial agreement among the member countries. These changes would be founded on the basic principles of free trade provided in NAFTA but modernizing and adjusting some components. For some sectors, particularly the energy sector, the proposed changes received heavy politicization and significant proposed adjustments. However, the transport sector was set to receive more support from the member states. The primary beneficiaries would be logistics services companies and transport modes, who would enjoy a reduced administrative burden and faster shipping times, translating into more revenues and fewer overheads.

With trucks moving about 70% of North American surface trade by value, trucking companies are set to be the biggest beneficiaries with the USMCA (https://ibn.fm/nCMq0). Fr8Tech, with its Fr8App, a B2B marketplace powered by Artificial Intelligence (“AI”) and Machine learning, looks to make cross-border shipping simple, safe and affordable. With the USMCA, the company looks to scale up its operations, grow its customer base and achieve even more growth going forward.

The objective for USMCA, as was the case with NAFTA, is to support mutually beneficial trade leading to more accessible markets, fairer trade, and robust economic growth in North America. It is specifically intended to grow various regional industries and sectors, and transportation is one of this transition’s primary beneficiaries. Fr8Tech recognizes this opportunity and is looking to bank on it to create shareholder value, grow its brand equity, and realize its short-term and long-term objectives.

For more information, visit the company’s website at www.Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Alternative Products Expo has just announced its next show, which will take place on March 3-5, 2023, in the beautiful city of Fort Lauderdale, Florida. This one-of-a-kind trade show promises to provide attendees with a unique experience that breaks away from the monotony of traditional events. It’s a must-attend for anyone in the smoke shop and counterculture industry.

Known for short as Alt Pro Expo, this event has its roots in the Vape and CBD world and has since expanded to include a plethora of industries. With over 200 exhibitors representing various product categories, such as Vape, CBD, Hemp, Delta-8, Nicotine Alternatives, Kratom, Extracts, Functional Beverages, tinctures, edibles, herbal products, mood enhancers, energy boosters, dietary supplements, and much more, there’s something for everyone to discover.

According to Jason Monti, the event’s co-founder, “ALT PRO Expo is more than just a trade show. It’s a platform for all counterculture professionals looking to expand or tap into this growing market.” And with thousands of registered buyers, prominent brands, and influential media partners participating, it’s an incredible opportunity for anyone looking to make new connections or showcase their products and services.

But the excitement doesn’t stop there. Florida is home to some of the most notable Alternative Product companies, and Fort Lauderdale, in particular, is a thriving hub for the counterculture industry. Attendees can take advantage of the many recreational activities in the area, such as boating, fishing, and sunbathing, making Alt Pro Expo the ideal destination for a productive and enjoyable trade show experience.

So mark your calendars and get ready to discover the latest and greatest in alternative products at the Alt Pro Expo. It’s an event you won’t want to miss!

For more information, please visit https://altproexpo.com/

Mining Journal Select Show on March 27-28th, 2023. An exclusive lineup of presenters will pitch their businesses in front of industry leaders and investors and get an opportunity for one-on-one meetings and personalized discussions with these eminent investment groups.

These mining companies presenting at Mining Journal Select are selected by the Mining Journal Research & Intelligence Team, who conduct research and analysis to shortlist a curated list of companies with exceptional potential and prospects. Investors looking for robust investment avenues can leverage this forum to discover aspiring mining businesses with exceptional qualities.

Aspiring and veteran miners and mining companies with bright and innovative ideas get to pitch their business prospects in front of an audience of over 400 institutional and retail investors. In addition, investors will be able to hold personalized meetings to analyze the mining presenting companies up close and personal. Presenting companies and other attendees associated with allied industries can participate in the 20+ pre-booked meetings to discuss their ideas directly with investors, as they connect and develop further networking ties over the two days of the event.

Mining Journal Select is one of the leading and established brands in the mining arena. Hence, attendees who are a part of the event have the opportunity to leverage the contacts and reach of Mining Journal and MiningNews.net. The company has an expansive reach with a global audience of 100,000 elite class and more than 1.5 million retail investors that were targeted via a CEO video interview.

Attendees get a chance to meet outstanding miners and come across new development projects in the mining segment. The event showcases a sophisticated audience that will get access to branded pods with screens to host the investor meets. About 800+ meetings between investors and mining companies will be hosted in the two days of the event. A dedicated concierge of experts focused on their jobs, will conduct and deliver 20+ meetings in an organized manner for each mining organization.

Some of the confirmed speakers for the upcoming event include:

• Alex Tsukernik, President & CEO Nova Royalty
• Barry Cahill, Executive Director, Cyprium Metals
• Brett Heath, President and CEO, Metalla Royalty & Streaming
• Bruce Griffin, Executive Chair, Sheffield Resources
• David Harquail, Chairman, Franco Nevada
• Mark Selby, Chairman & CEO, Canada Nickel
• … plus much more

In addition, 4 expert panel sessions will offer insights and support the communication and networking between mining companies and investors.

Join in for 14+ hours of interactive mining discussions, networking and interactions that will pave way for long-term business ties.

To learn more, please visit (https://ibn.fm/xSYj2).

• SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females”
• Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD
• Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease
• Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females”, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions.

SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD.

“After a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD, and related disorders,” said SILO Chief Executive Officer Eric Weisblum.

SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease.

Several therapeutics developed by the company may qualify for the FDA’s streamlined 505(b)(2) regulatory drug approval pathway. Drugs that qualify under the 505(b)(2) pathway may be exempted from conducting repeat studies previously performed on tested drugs, enabling the company to reduce expenses and speed up the time to market (https://ibn.fm/BiKBw). Other benefits include lower treatment risk due to previous drug approval and the potential to qualify for 3-7 years of market exclusivity.

Silo Pharma Inc. merges traditional therapeutics with psychedelic research to develop innovative therapeutics for underserved markets, including PTSD, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological conditions. The company collaborates with top universities and research institutions to develop therapeutics that can improve patient outcomes and potentially transform the healthcare industry.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO